Sign up to our newsletter Subscribe
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Alongside our research reports we provide insightful comment and analysis on a wide range of issues. We also invite guest authors to provide their perspectives.
The latest news and comment from OHE experts
Our monthly Bulletin highlights our work alongside the latest from across health economics and health care.